On March 18, 2015, Dr. Gautam Shah, the Executive Vice President and Chief Regulatory Officer of Achillion Pharmaceuticals, Inc., provided notice of his departure from the Company effective March 31, 2015. Subject to Dr. Shah executing a release of all claims against the Company and its affiliates, Dr. Shah will be entitled to receive benefits pursuant to the terms of his employment agreement dated April 5, 2011. Dr. Shah will continue to be subject to the terms of a Non-Competition and Non-Solicitation Agreement and a Non-Disclosure and Assignment of Inventions Agreement previously entered into with the Company.